Details

Indicated for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS  >=1), as determined by an FDA-approved test.

type

FDA Approval

approval date

2021-10-13

settings
settings
Metastatic
settings
Recurrent
source

FDA